Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002961463 | SCV003686439 | uncertain significance | Inborn genetic diseases | 2020-11-05 | criteria provided, single submitter | clinical testing | The c.358A>G (p.I120V) alteration is located in exon 5 (coding exon 5) of the CCDC88C gene. This alteration results from a A to G substitution at nucleotide position 358, causing the isoleucine (I) at amino acid position 120 to be replaced by a valine (V). Based on data from the Genome Aggregation Database (gnomAD) database, the CCDC88C c.358A>G alteration was observed in 0.04% (104/280508) of total alleles studied, with a frequency of 0.9% (93/10350) in the Ashkenazi Jewish subpopulation. This amino acid position is not well conserved in available vertebrate species. The p.I120V alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003546928 | SCV004266704 | benign | not provided | 2024-08-12 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004553846 | SCV004747435 | benign | CCDC88C-related disorder | 2019-07-04 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |